(Q40192653)

18 September 2017

title

Contribution of Major Metabolites toward Complex Drug-Drug Interactions of Deleobuvir: In Vitro Predictions and In Vivo Outcomes (English)

1 reference

18 September 2017

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26684498%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

author name string

Rucha S Sane

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26684498%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

John P Sabo

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26684498%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Curtis Cooper

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26684498%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Lois Rowland

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26684498%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Naitee Ting

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26684498%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Andrea Whitcher-Johnstone

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26684498%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Donald J Tweedie

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26684498%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

publication date

18 December 2015

1 reference

Drug Metabolism and Disposition

18 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26684498%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

volume

44

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26684498%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26684498%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

page(s)

466-475

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26684498%20AND%20SRC:MED&resulttype=core&format=json

CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe

9 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.066985

Effect of peginterferon alfa-2a (40KD) on cytochrome P450 isoenzyme activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.066985

Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.066985

Drug metabolites as cytochrome p450 inhibitors: a retrospective analysis and proposed algorithm for evaluation of the pharmacokinetic interaction potential of metabolites in drug discovery and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.066985

Mass balance, metabolite profile, and in vitro-in vivo comparison of clearance pathways of deleobuvir, a hepatitis C virus polymerase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.066985

In vitro and in vivo induction of cytochrome p450: a survey of the current practices and recommendations: a pharmaceutical research and manufacturers of america perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.066985

Evaluation of various static and dynamic modeling methods to predict clinical CYP3A induction using in vitro CYP3A4 mRNA induction data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.066985

Time response of cytochrome P450 1A2 activity on cessation of heavy smoking

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.066985

Prediction of drug-drug interactions from in vitro induction data: application of the relative induction score approach using cryopreserved human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.066985

Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.066985

Cytochrome P450 3A4 mRNA is a more reliable marker than CYP3A4 activity for detecting pregnane X receptor-activated induction of drug-metabolizing enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.066985

A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.066985

Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.066985

Effects of multiple-dose pegylated interferon alfa-2b on the activity of drug-metabolizing enzymes in persons with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.066985

Multiple inhibition mechanisms and prediction of drug-drug interactions: status of metabolism and transporter models as exemplified by gemfibrozil-drug interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.066985

CYP induction-mediated drug interactions: in vitro assessment and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.066985

Stereoselective inhibition of CYP2C19 and CYP3A4 by fluoxetine and its metabolite: implications for risk assessment of multiple time-dependent inhibitor systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.066985

Defining the Role of Gut Bacteria in the Metabolism of Deleobuvir: In Vitro and In Vivo Studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.066985

Arsenite and its metabolites, MMA(III) and DMA(III), modify CYP3A4, PXR and RXR alpha expression in the small intestine of CYP3A4 transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.066985

Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.066985

Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.066985

General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.066985

Phase 2 enzyme induction by the major metabolite of oltipraz

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.066985

Carboxymefloquine, the major metabolite of the antimalarial drug mefloquine, induces drug-metabolizing enzyme and transporter expression by activation of pregnane X receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.066985

Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut - the effect of diltiazem on th

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.066985

Interactions of the hepatitis C virus protease inhibitor faldaprevir with cytochrome P450 enzymes: in vitro and in vivo correlation

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.066985

A comprehensive assessment of repaglinide metabolic pathways: impact of choice of in vitro system and relative enzyme contribution to in vitro clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.066985

Modeling, prediction, and in vitro in vivo correlation of CYP3A4 induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.066985

Current industrial practices in assessing CYP450 enzyme induction: preclinical and clinical

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.066985

Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.066985

Quantitative prediction of repaglinide-rifampicin complex drug interactions using dynamic and static mechanistic models: delineating differential CYP3A4 induction and OATP1B1 inhibition potential of rifampicin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.066985

Drug-drug interactions via mechanism-based cytochrome P450 inactivation: points to consider for risk assessment from in vitro data and clinical pharmacologic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.066985

Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug-drug interaction risk assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.066985

Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.066985

Contribution of metabolites to P450 inhibition-based drug-drug interactions: scholarship from the drug metabolism leadership group of the innovation and quality consortium metabolite group

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.066985

Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.066985

Faldaprevir and deleobuvir for HCV genotype 1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.066985

A multi-endpoint evaluation of cytochrome P450 1A2, 2B6 and 3A4 induction response in human hepatocyte cultures after treatment with β-naphthoflavone, phenobarbital and rifampicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.066985

Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.066985

Insights into the structure, function, and regulation of human cytochrome P450 1A2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.066985

Glucuronidation Converts Clopidogrel to a Strong Time-Dependent Inhibitor of CYP2C8: A Phase II Metabolite as a Perpetrator of Drug–Drug Interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1124%2FDMD.115.066985